

Naphthoquinone and Iridoid with NGF-potentiating Activity from *Verbena littoralis*

Yushan Li, Masayuki Satake,[†] Yasukatsu Oshima,[†] and Yasushi Ohizumi*


Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai 980-8578

[†]Graduate School of Life Sciences, Tohoku University, Aoba-ku, Sendai 981-8555

(Received June 5, 2003; CL-030501)

One new naphthoquinone, (4*R*)-4,9-dihydroxy-8-methoxy- α -lapachone (**1**), and two new iridoids, 7*a*-hydroxygelsemiol (**2**) and 6-methoxysemperoside (**3**) were isolated from *Verbena littoralis* H. B. K. **1** (3–30 μ M) and **2** (3 μ M) showed a markedly enhancing activity of nerve growth factor (NGF)-mediated neurite outgrowth from PC12D cells.

The aerial parts of *Verbena littoralis* H. B. K. (Verbenaceae) from Paraguay gave a methanol extract that showed an enhancing activity of NGF-mediated neurite outgrowth from PC12D cells. We isolated active components **1** and **2** as enhancers of NGF action from the extract by activity-guided fractionation and **3**. Compounds that possess this property may be useful in the treatment of neurodegenerative diseases including cerebrovascular dementia, Parkinson's disease, and Alzheimer's disease.^{1,2}



The MeOH extracts of *V. littoralis* (5 kg) were partitioned into EtOAc, *n*-BuOH and H₂O three fractions. The EtOAc and *n*-BuOH soluble materials were separated by a series of bioassay-directed chromatographic separations employing silica gel column, Sephadex LH-20 column and semi-preparative HPLC column chromatography (YMC-pack NH₂ A-624 and YMC-AM-324 ODS) to yield **1** (2.2 mg), **2** (22.9 mg), and **3** (13.4 mg).

Compound **1** was obtained as red amorphous powder, and its molecular formula was determined to be C₁₆H₁₆O₆ by HREIMS [*m/z* 304.0905, Δ -4.2 mmu]. The IR spectrum showed the presence of hydroxyl (3600–3300 cm⁻¹) and carbonyl (1640 and 1610 cm⁻¹) moieties. A detailed examination of the ¹H and ¹³C NMR spectral data of **1**, aided by DEPT and HMQC experiments, disclosed the presence of two carbonyls, six *sp*² quaternary carbons (three of which were oxygen-bearing), one *sp*³ oxygen-bearing quaternary carbon, one *sp*³ oxygen-bearing methine, two *sp*² methine, one *sp*³ methylene, one methoxyl, and two methyl groups.

In the ¹H NMR spectrum of **1**, a pair of *ortho*-coupled aromatic proton signals at δ 7.63 (1H, *J* = 8.5 Hz, H-6) and 7.06 (1H, *J* = 8.5 Hz, H-7) were positioned to the C-6 (δ _C 120.24) and C-7 (δ _C 115.53) by the HMBC correlations of H-6/C-5 (δ _C 184.43), H-6/C-8 (δ _C 153.88) and H-6/C-9*a* (δ _C 114.29), and H-7/C-5*a* (δ _C 125.47) and H-7/C-9 (δ _C 152.63),

respectively (Figure 1). Two hydroxyl proton signals at δ 12.16 (9-OH) and 3.83 (4-OH) were assigned to the C-9 and C-4 (δ _C 60.12), correspondingly, because the proton of the 9-OH correlated with C-8, C-9 and C-9*a*, and H-4 (δ 4.93) correlated with C-2 (δ _C 79.83), C-5 and C-10*a* (δ _C 153.57) in the HMBC spectrum. A methoxyl signal at δ 3.97 (3H, s) was placed at the C-8 by the HMBC correlation of 8-OCH₃/C-8. A pair of gem-dimethyl signals at δ 1.43 (3H, s, H₃-11) and 1.54 (3H, s, H₃-12) were located at C-2 on the basis of the interaction peaks of H₃-11/C-2, H₃-12/C-2, H₃-11/C-12 (δ _C 27.08), and H₃-12/C-11 (δ _C 26.70) of the HMBC spectrum. The remaining signals of ¹H and ¹³C NMR spectra can be entirely assigned by the analysis of DEPT, ¹H-¹H COSY, HMQC and HMBC spectral data. The absolute configuration remained undetermined by a negative optical rotation, because the absolute configuration of a similar compound 4-hydroxy-9-methoxy- α -lapachone had been determined to be *S* which shown a positive optical rotation.³ On the basis of the above evidences, the structure of **1** was elucidated as (4*R*)-4,9-dihydroxy-8-methoxy- α -lapachone.⁴

Compound **2** was obtained as a colorless amorphous solid and its molecular formula C₁₀H₁₆O₅ was determined by HRFABMS *m/z* 217.1088 [M+H]⁺ (calcd, 217.1076). The IR spectrum indicated the presence of hydroxyl (3600–3100 cm⁻¹) and lactone (1745 cm⁻¹) moieties. Comprehensive analysis of NMR spectral data, especially ¹H-¹H COSY, HMQC and HMBC data, revealed the structure of **2**. In the ¹H NMR spectrum of **2**, two pairs of oxygen-bearing methylene proton signals at δ 3.64 (1H, d, *J* = 12.0 Hz, H-1*a*) and δ 3.61 (1H, d, *J* = 12.0 Hz, H-1*b*), and at δ 3.88 (1H, dd, *J* = 10.8, 4.2 Hz, H-3*a*) and δ 3.86 (1H, dd, *J* = 10.8, 4.8 Hz, H-3*b*) were positioned to the C-1 (δ _C 66.27) and C-3 (δ _C 63.88), respectively, by the HMBC correlations of H-1*a* (H-1*b*) with C-4*a* (δ _C 54.86), C-7 (δ _C 38.08) and C-7*a* (δ _C 85.32), H-3*a* (H-3*b*) with C-4 (δ _C 47.40), C-4*a* and C-9 (δ _C 181.41). One doublet signal at δ _C 0.94 (3H, d, *J* = 6.6 Hz, H₃-8) was assigned to the methyl carbon C-8 (δ _C 12.68) by the cross peak H₃-8/H-7 (δ 1.76) of the ¹H-¹H COSY spectrum and the HMBC correlations of C-8/H-6 (δ 1.92, 1.95), C-8/H-7, H₃-8/C-6 (δ _C 40.67), H₃-8/C-7 and H₃-8/C-7*a*. The presence of a five-membered lactone ring was deduced by the analysis of the downfield chemical shift signals at δ 4.99 (1H, ddd, *J* = 7.2, 5.4, 1.2 Hz, H-5), which revealed that the methine (δ _C 85.08, C-5) was linked to an acyloxy group, and this was confirmed by the HMBC correlations of C-9 with H-3, H-4 (δ 2.85), H-4*a* (δ 2.96) and H-5. The cyclopentane ring was determined by the analysis of ¹H-¹H COSY and HMBC spectral data (Figure 1). The relative stereochemistry of **2** was established by NOESY spectrum data (Figure 1). The correlations of H-3*a*/H-4*a*, H-4*a*/H-5, H-5/H-




Figure 1. Selected correlations of HMBC, NOESY and ^1H - ^1H COSY of **1-3**.

6β , and $\text{H-}6\beta/\text{H}_3\text{-}8$ suggested that the $\text{H-}4\text{a}$, $\text{H-}5$, $\text{H-}6\beta$, $4\text{-CH}_2\text{OH}$, and 7-CH_3 groups oriented on the same side of the planar structure in the β -positions. The observed NOEs from $\text{H-}1\text{b}$ to $\text{H-}4$ and $\text{H-}7$, from $\text{H-}7$ to $\text{H-}6\alpha$ suggested that the $\text{H-}4$, $\text{H-}6\alpha$, $\text{H-}7$, and $7\text{a-CH}_2\text{OH}$ were in the β -position as well as 7a-OH was in the β -position. Thus, the structure of **2** was determined to be $7\text{a-hydroxygelsemiol}$ by the above analysis.⁵

The positive ion FABMS of **3** gave a quasimolecular ion peak $[\text{M} + \text{Na}]^+$ at m/z 413 and the molecular formula was determined to be $\text{C}_{17}\text{H}_{26}\text{O}_{10}$ by HRFABMS (m/z 413.1435, $\Delta + 1.2$ mmu, $[\text{M} + \text{Na}]^+$). ^1H and ^{13}C NMR spectral data of **3** revealed the presence of one ester carbonyl, twelve sp^3 methine (eight of which were oxygen-bearing), two sp^3 oxygen-bearing methylene, one methyl, and one methoxyl groups. The initial analysis of the NMR spectral data indicated that the molecule consist of a monoterpene iridoid and a sugar moiety. Comparing the ^1H and ^{13}C NMR spectral data with those of semperoside,⁶ we saw almost complete coincidence for all the signals, except for one methoxyl group (δ_{C} 49.85; δ 3.29, 3H, s) which was assigned to the C-6 (δ_{C} 77.78) by the correlation of C-6/6-OCH₃ in the HMBC spectrum (Figure 1). Thus, the structure of **3** was determined to be 6-methoxysemperoside.⁷ Stereochemistry of **3** was determined as shown by the NOESY spectrum and the analysis of coupling constants. $\text{H-}4$, $\text{H-}4\text{a}$, $\text{H-}5$, $\text{H-}7\text{a}$, and 7-CH_3 were in the β -position, because of the presence of cross-peaks of $\text{H-}4/\text{H-}4\text{a}$, $\text{H-}4\text{a}/\text{H-}5$, $\text{H-}4\text{a}/\text{H-}7\text{a}$, and $\text{H-}7\text{a}/7\text{-CH}_3$. The β -position of 6-OCH₃ was assigned by the correlation of $\text{H-}6/\text{H-}7$ in the NOESY spectrum. The configuration at C-3 had the oxygen in the β -position, with the proton α , like other iridoids including semperoside,⁶ from the detailed analysis of the molecular model of **3** on the basis of following observation; 1) $\text{H-}3$ appeared as a singlet, so the angle between $\text{H-}3$ and $\text{H-}4$ should be near 90° , 2) there were NOEs between $\text{H-}3$ and $\text{H-}4$ and between $\text{H-}1$ and $\text{H-}1'$, but not NOEs of $\text{H-}3/\text{H-}4\text{a}$ and $\text{H-}3/\text{H-}1\alpha$ ($\text{H-}1\beta$).

The ability of **1-3** to enhance NGF's effects for stimulating neurite outgrowth from PC12D cells was assessed utilizing methodology previously reported.⁸ **1** (3, 10, and $30\ \mu\text{M}$) and **2**

($3\ \mu\text{M}$) did not induced neurite outgrowth from PC12D cells in the absence of NGF, but increased the NGF-induced proportion (2 ng/mL, 25%) of neurite-bearing cells by 30.2%, 34.2%, 40.05 and 40.3%, respectively. Increasing the concentrations of **2** from $3\ \mu\text{M}$ to 10 or $30\ \mu\text{M}$ showed the cytotoxicity on PC12D cells.

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References and Notes

- G. J. Siegel and N. B. Chauhan, *Brain Res. Rev.*, **33**, 199 (2000).
- Y. Fukuyama, K. Nakade, Y. Minoshima, R. Yokoyama, H. Zhai, and Y. Mitsumoto, *Bioorg. Med. Chem. Lett.*, **12**, 1163 (2002).
- H. Itokawa, K. Matsumoto, H. Morita, and K. Takeya, *Phytochemistry*, **31**, 1061 (1992).
- 1**: mp 151-153 °C; $[\alpha]_{\text{D}}^{30}$ -40.9° ($c = 0.13$, CHCl_3); UV (MeOH) λ_{max} 211 (log ϵ , 4.2), 227 (4.0), 262 (2.8), 301 (2.4), 433 (2.1) nm; IR (neat) 3600-3300 (br, OH), 1640, 1610, 1460 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 12.16 (s, 9-OH), 7.63 (1H, d, $J = 8.5$ Hz, H-6), 7.06 (1H, d, $J = 8.5$ Hz, H-7), 4.93 (1H, t, $J = 6.5$ Hz, H-4), 3.97 (3H, s, 8-OCH₃), 3.83 (s, 4-OH), 2.11 (1H, dd, $J = 14.5$, 6.0 Hz, H-3 α), 2.01 (1H, dd, $J = 14.5$, 6.5 Hz, H-3 β), 1.54 (3H, s, H₃-12), 1.43 (3H, s, H₃-11); ^{13}C NMR (150 MHz, CDCl_3) δ 185.40 (s, C-10), 184.43 (s, C-5), 153.88 (s, C-8), 153.57 (s, C-10a), 152.63 (s, C-9), 125.47 (s, C-5a), 123.58 (s, C-4a), 120.24 (d, C-6), 115.53 (d, C-7), 114.29 (s, C-9a), 79.83 (s, C-2), 60.12 (d, C-4), 56.40 (q, 8-OCH₃), 39.60 (t, C-3), 27.08 (q, C-12), 26.70 (q, C-11); EIMS m/z 304 $[\text{M}]^+$ (51.8), 271 (9.2), 248 (34.5), 220 (43.6), 202 (36.4), 192 (42.0), 151 (10.6), 83(100); HREIMS m/z 304.0905 $[\text{M}]^+$ (Calcd for $\text{C}_{16}\text{H}_{16}\text{O}_6$, 304.0945), 248.0297 $[\text{M-C}_4\text{H}_8]^+$ (Calcd for $\text{C}_{12}\text{H}_8\text{O}_6$, 248.0320).
- 2**: mp 143-145 °C; $[\alpha]_{\text{D}}^{30}$ -8.7° ($c = 0.33$, CH_3OH); UV (MeOH) λ_{max} 214 (log ϵ , 4.3), 281 (3.5), 310 (sh.) nm; IR (neat) 3600-3100 (br, OH), 1745 cm^{-1} ; ^1H NMR (600 MHz, CD_3OD) δ 4.99 (1H, ddd, $J = 7.2$, 5.4, 1.2 Hz, H-5), 3.88 (1H, dd, $J = 10.8$, 4.2 Hz, H-3a), 3.86 (1H, dd, $J = 10.8$, 4.8 Hz, H-3b), 3.64 (1H, d, $J = 12.0$ Hz, H-1a), 3.61 (1H, d, $J = 12.0$ Hz, H-1b), 2.96 (1H, dd, $J = 7.2$, 6.0 Hz, H-4a), 2.85 (1H, ddd, $J = 6.0$, 4.8, 4.2 Hz, H-4), 1.98 (1H, m, H-7), 1.95 (1H, ddd, $J = 14.4$, 5.4, 1.2 Hz, H-6 β), 1.92 (1H, dd, $J = 14.4$, 5.4 Hz, H-6 α), 0.94 (3H, d, $J = 6.6$ Hz, H₃-8); ^{13}C NMR (150 MHz, CD_3OD) δ 181.41 (s, C-9), 85.32 (s, C-7a), 85.08 (d, C-5), 66.27 (t, C-1), 63.88 (t, C-3), 54.86 (d, C-4a), 47.40 (d, C-4), 40.67 (t, C-6), 38.08 (d, C-7), 12.68 (q, C-8); FABMS m/z 239 $[\text{M}+\text{Na}]^+$ (12), 217 $[\text{M}+\text{H}]^+$ (100), 185 (30), 181 (19), 93 (86); HRFABMS m/z 217.1088 $[\text{M}+\text{H}]^+$ (Calcd for $\text{C}_{10}\text{H}_{17}\text{O}_5$, 217.1076).
- S. R. Jensen, O. Kirk, B. J. Nielsen, and R. Norrestam, *Phytochemistry*, **31**, 1061 (1992).
- 3**: mp 138-140 °C; $[\alpha]_{\text{D}}^{30}$ $+29.1^\circ$ ($c = 0.30$, CH_3OH); UV (MeOH) λ_{max} 206 (log ϵ , 3.8), 277 (1.9) nm; IR (neat) 3600-3300 (br, OH), 1760 cm^{-1} ; ^1H NMR (500 MHz, CD_3OD) δ 5.30 (1H, s, H-3), 4.68 (1H, d, $J = 6.5$ Hz, H-5), 4.46 (1H, d, $J = 8.0$ Hz, H-1'), 4.39 (1H, dd, $J = 12.5$, 3.5 Hz, H-1 β), 3.93 (1H, d, $J = 3.0$ Hz, H-6), 3.80 (1H, dd, $J = 12.0$, 2.0 Hz, H-6'b), 3.65 (1H, dd, $J = 12.0$, 5.0 Hz, H-6'a), 3.44 (1H, d, $J = 12.5$ Hz, H-1 α), 3.34 (1H, t, $J = 9.0$ Hz, H-3'), 3.30 (1H, ddd, $J = 9.0$, 5.0, 2.0 Hz, H-5'), 3.29 (3H, s, 6-OCH₃), 3.28 (1H, t, $J = 9.0$ Hz, H-4'), 3.25 (1H, dd, $J = 11.0$, 6.5 Hz, H-4a), 3.18 (1H, dd, $J = 9.0$, 8.0 Hz, H-2'), 2.97 (1H, d, $J = 11.0$ Hz, H-4), 1.82 (1H, m, H-7), 1.75 (1H, ddd, $J = 13.0$, 12.0, 4.5 Hz, H-7a), 0.98 (3H, d, $J = 6.5$ Hz, H₃-8); ^{13}C NMR (125 MHz, CD_3OD) δ 177.65 (s, C-9), 103.97 (d, C-1'), 98.66 (d, C-3), 88.28 (d, C-5), 78.33 (d, C-5'), 77.99 (d, C-3'), 77.78 (d, C-6), 75.35 (d, C-2'), 71.33 (d, C-4'), 62.62 (t, C-6'), 57.45 (t, C-1), 49.85 (q, 6-OCH₃), 41.97 (d, C-4), 38.57 (d, C-7a), 38.11 (d, C-7), 35.64 (d, C-4a), 11.02 (q, C-8); FABMS m/z 413 $[\text{M}+\text{Na}]^+$ (20), 391 $[\text{M}+\text{H}]^+$ (5), 304 (10), 282 (50), 256(13), 197 (32), 155 (73), 136 (78), 107 (47); HRFABMS m/z 413.1435 $[\text{M}+\text{Na}]^+$ (Calcd for $\text{C}_{17}\text{H}_{26}\text{O}_{10}\text{Na}$, 413.1424), 197.0842 $[\text{C}_{10}\text{H}_{13}\text{O}_4]^+$ (Calcd for 197.0814).
- Y. Li, K. Matsunaga, R. Kato, and Y. Ohizumi, *J. Pharm. Pharmacol.*, **53**, 915 (2001).